Associated Banc Corp decreased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 72.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,032 shares of the biopharmaceutical company’s stock after selling 80,199 shares during the period. Associated Banc Corp’s holdings in Celgene were worth $2,834,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Investors Research Corp bought a new position in shares of Celgene during the first quarter valued at approximately $28,000. Creative Financial Designs Inc. ADV increased its position in shares of Celgene by 1,968.8% during the first quarter. Creative Financial Designs Inc. ADV now owns 331 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 315 shares in the last quarter. Bruderman Asset Management LLC bought a new stake in shares of Celgene during the fourth quarter valued at approximately $25,000. Murphy Pohlad Asset Management LLC bought a new stake in shares of Celgene during the fourth quarter valued at approximately $25,000. Finally, Athena Capital Advisors LLC bought a new stake in shares of Celgene during the fourth quarter valued at approximately $27,000. 70.78% of the stock is owned by institutional investors and hedge funds.
NASDAQ:CELG opened at $95.63 on Friday. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.07. The company has a market capitalization of $67.96 billion, a price-to-earnings ratio of 12.57, a P/E/G ratio of 0.44 and a beta of 1.68.
CELG has been the subject of several analyst reports. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research report on Friday, February 1st. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. William Blair reissued a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Cantor Fitzgerald downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price target for the company. in a research report on Friday, April 5th. Finally, Cowen initiated coverage on shares of Celgene in a research report on Tuesday, February 26th. They set a “market perform” rating and a $102.00 price target for the company. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $95.56.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: Blue-Chip Stocks
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.